View Older Stories View More Recent Stories

Sep 24, 2024 08:00AM Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Sep 23, 2024 09:25AM Capricor Therapeutics (CAPR) to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 23, 2024 09:25AM Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 17, 2024 09:17AM Capricor Therapeutics (CAPR) Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Sep 17, 2024 09:15AM Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Sep 6, 2024 08:30AM Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Aug 7, 2024 04:05PM Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 31, 2024 09:00AM Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
Jul 1, 2024 09:00AM Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
Jun 28, 2024 09:00AM Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Jun 25, 2024 10:30AM CORRECTION: Capricor Therapeutics
Jun 25, 2024 08:32AM Capricor Therapeutics (CAPR) announces FDA has scheduled Pre-BLA meeting for deramiocel to treat DMD
Jun 25, 2024 08:30AM Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Jun 11, 2024 09:25AM Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002 Program
Jun 11, 2024 09:25AM Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Jun 4, 2024 09:03AM Capricor Therapeutics (CAPR) Reports Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002
Jun 4, 2024 09:00AM Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
May 13, 2024 04:05PM Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024 09:15AM Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
May 8, 2024 09:00AM Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
May 6, 2024 09:00AM Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Apr 24, 2024 09:00AM Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002
Apr 24, 2024 09:00AM Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Mar 21, 2024 08:30AM Capricor Therapeutics to Present at Upcoming Investor Conferences
Mar 6, 2024 08:30AM Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 29, 2024 04:05PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Feb 27, 2024 08:33AM Capricor Therapeutics (CAPR) Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in DMD
Feb 27, 2024 08:30AM Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Feb 22, 2024 08:30AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Feb 20, 2024 08:31AM Capricor Therapeutics (CAPR) Announces Manufacturing Scale-Up of CAP-1002 Production
Feb 20, 2024 08:30AM Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Jan 24, 2024 09:15AM Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Dec 11, 2023 09:00AM Capricor Therapeutics (CAPR) Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 Based on Completion of Interim Futility Analysis
Dec 11, 2023 09:00AM Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Nov 14, 2023 04:05PM Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 7, 2023 09:15AM Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Oct 19, 2023 04:01PM Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
Oct 10, 2023 09:00AM Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
Sep 29, 2023 07:31AM Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Sep 29, 2023 07:30AM Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Sep 6, 2023 09:05AM Capricor Therapeutics (CAPR) Appoints Michael Kelliher to its Board
Sep 6, 2023 09:00AM Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
Aug 7, 2023 04:05PM Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 2, 2023 04:01PM Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Jul 24, 2023 08:33AM Capricor Therapeutics (CAPR) Appoints Philip J. Gotwals to its Board
Jul 24, 2023 08:30AM Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
Jul 13, 2023 08:32AM Capricor Therapeutics (CAPR) Appoints Paul Auwaerter to its Board
Jul 13, 2023 08:30AM Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
Jun 30, 2023 09:25AM Capricor Therapeutics (CAPR) Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Jun 30, 2023 09:25AM Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
View More Recent Stories View Older Stories